Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of DISC-0974 in Healthy Volunteers
NCT04999527Phase 1Completed
- Sponsor
- Disc Medicine
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in anemia of chronic disease (ACD) comparing DISC-0974 with Placebo (2 arms). Primary endpoints: Incidence of adverse events up to 71 days, Incidence of abnormal laboratory test results up to 71 days and 2 more. Started Aug 2021; status: completed.
02
Drugs
selcodebart
03
Conditions
anemia of chronic disease (ACD)
Beyond the preview
Go deeper on NCT04999527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999527.